Generic Topicort Availability
TOPICORT (desoximetasone - ointment;topical)
TOPICORT (desoximetasone - spray;topical)
Has a generic version of Topicort been approved?
No. There is currently no therapeutically equivalent version of Topicort available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topicort. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Composition and method for treatment of psoriasis
Issued: November 23, 1999
Inventor(s): Rosenberg; E. William & Glenn; Thomas M. & Skinner, Jr.; Robert B. & Noah; Patricia W.
Assignee(s): Panda Pharmaceuticals, L.L.C. The University of Tennessee Research Corporation
Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.Patent expiration dates:
- March 24, 2018✓✓
- March 24, 2018
Stable liquid desoximethasone compositions with reduced oxidized impurity
Issued: October 2, 2012
Inventor(s): Rao; Srinivasa & Dixit; Suresh & Yacobi; Avraham & Bailey; Arthur
Assignee(s): Taro Pharmaceutical North America, Inc.
The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9α-fluoro-11β-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.Patent expiration dates:
- April 23, 2028✓✓
- April 23, 2028
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 11, 2016 - NEW DOSAGE FORM
- Topicort cream Consumer Information (Wolters Kluwer)
- Topicort gel Consumer Information (Wolters Kluwer)
- Topicort spray Consumer Information (Wolters Kluwer)
- Topicort Consumer Information (Cerner Multum)
- Topicort Advanced Consumer Information (Micromedex)
- Topicort Mild Advanced Consumer Information (Micromedex)
- Topicort AHFS DI Monographs (ASHP)
- Desoximetasone cream Consumer Information (Wolters Kluwer)
- Desoximetasone gel Consumer Information (Wolters Kluwer)
- Desoximetasone spray Consumer Information (Wolters Kluwer)
- Desoximetasone topical Consumer Information (Cerner Multum)
- Desoxi Advanced Consumer Information (Micromedex)
- Taro-Desoximetasone Advanced Consumer Information (Micromedex)
- Desoximetasone Topical application Advanced Consumer Information (Micromedex)
- Desoximetasone AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|